Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.

Shah, Dhvani; Driessen, Maurice; Risebrough, Nancy; Baker, Timothy; Naya, Ian; Briggs, Andrew; Ismaila, Afisi S

Shah, Dhvani; Driessen, Maurice; Risebrough, Nancy; Baker, Timothy; Naya, Ian; Briggs, Andrew; Ismaila, Afisi S.

Affiliation

Shah D; ICON Health Economics, ICON, New York, NY USA.
Driessen M; 2Value Evidence & Outcomes, GSK, Brentford, Middlesex, UK.
Risebrough N; ICON Health Economics, ICON, Toronto, ON Canada.
Baker T; ICON Health Economics, ICON, New York, NY USA.
Naya I; 4Respiratory Medical Franchise, GSK, Brentford, Middlesex, UK.
Briggs A; 5Health Economics & Health Technology Assessment Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK.
Ismaila AS; 6Value Evidence & Outcomes, GSK, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398 USA.

Cost Eff Resour Alloc ; 16: 17, 2018.

Article in En | MEDLINE | ID: mdl-29773969

Key words

Chronic obstructive pulmonary disorder; Cost-effectiveness; Economic evaluation; Long-acting muscarinic antagonist

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Language: En Journal: Cost Eff Resour Alloc Year: 2018 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google